: Patients were divided into a focal group (n=47, including 40 focal adenomyosis and 7 adenomyoma cases) and a non-focal group (n=60, including 36 diffuse and 24 mixed adenomyosis cases) according to the extent of lesion involvement.

: We collected and analyzed preoperative baseline data on patient characteristics, postoperative efficacy measures at 3, 6, and 12 months, and intra- and post-operative complications. There was a significant post-treatment reduction in the uterine corpus volume and cancer antigen 125 (CA125) levels, an increase in hemoglobin (Hb) levels, and an improvement in the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) scores (consisting of the Symptom Severity Scale [SSS] and the Health-related Quality of Life scale [HRQL]), dysmenorrhea visual analog scale (VAS), and menstrual volume scores (MVS) (all P<.05). One patient had recurrence. Most adverse events (72.0%) were mild. Although the non-focal group had significantly greater anemia severity, higher SSS and MVS, lower HRQL, greater extent and severity of myometrial involvement, and larger uterine corpus volume, post-treatment the uterine corpus volume, uterine corpus reduction rate, CA125 levels, Hb levels, UFS-QOL score, dysmenorrhea VAS, MVS score, and clinical response rate were similar between the groups (P>.05).